Yet, despite the “stormy waters,” global sales of orphan drugs are projected to exceed $400 billion by 2032, according to a new report by Evaluate.

"The stories are so outrageous," Senator Ron Johnson said. "It just appears that they’re looking for excuses to say no." ...

Analysts expect the market for manufacturing cell and gene therapies, worth less than $20 billion in 2024, to expand rapidly as approvals drive higher volumes of production.

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a ...

The complex procedure, carried out at Gleneagles Hospital in Parel, used a single liver from a 38-year-old brain-dead donor ...

GeneDx Holdings WGS announced a sponsored genetic testing program with Zevra Therapeutics to improve diagnosis for patients ...

This research highlights the scale and clinical impact of GeneDx Infinity™ - the largest and most comprehensive rare disease genomic dataset - and GeneDx's leadership in bringing exome and genome ...

Oppenheimer initiated coverage of Ocugen (NASDAQ:OCGN) with an Outperform rating and a $10 price target on Wednesday, positioning the clinical-stage gene therapy company as an emerging leader in ...

For their discovery of genomic imprinting, developmental biologists Davor Solter and Azim Surani will receive the 2026 Paul Ehrlich and Ludwig ...

Some biotechs that had seen regulatory setbacks under Center for Biologics Evaluation and Research director Vinay Prasad experienced stock bumps Monday morning. Under Prasad’s leadership, the rare ...

Precision breeding, including techniques such as gene editing, is one of the core disciplines that researchers at Norwich Research Park have been employing for many years in their bid to help solve ...

If you are fried from constant fires at work but still need a real income, you are not alone. And there are careers that ...